Compare Applovin Corporation (APP) vs Twist Bioscience Corp (TWST) Price & Performance

AppLovin (APP) trades at $303.76, down 10.4% in the last 24 hours, reflecting recent bearish sentiment driven by a Q2 earnings miss and a Bank of America downgrade. Despite strong fundamentals with 53% revenue growth in Q2 2026 and a net income margin of 64.58%, technical indicators show a bearish trend with the current price below key support levels. The stock faces near-term pressure from concerns over sustainable growth, though analyst consensus remains largely bullish with an average price target of $556.53.

The outlook for APP hinges on its ability to maintain high growth rates amid execution risks. While valuation multiples like a P/E of 24.5 appear reasonable given profitability, investors face volatility from competitive threats and model-dependent revenue growth. The stock offers upside if Q3 results beat expectations, but caution is warranted due to recent institutional selling and mixed technical signals.

Twist Bioscience (TWST) trades at $125.13, up 0.2% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported Q3 2026 revenue of $118.4 million, up 23% year-over-year, beating estimates, but posted a net loss. Revenue growth is strong, yet profitability remains elusive with negative margins. Recent news highlights an upsized $300 million public offering and expanding AI drug discovery pipeline.

Outlook is mixed: robust revenue growth and analyst optimism (78.57% buy ratings) support upside, but persistent losses, cash burn, and high valuation multiples pose significant risks. The stock's proximity to resistance at $126 suggests near-term volatility. Investors should weigh growth potential against financial sustainability concerns.